



A SMALL

BIOTECH COMPANY

BUILT ON A

BIG DREAM

At BioCryst, we're committed to discovering and developing treatments that are not only potentially life-saving—but extraordinary—because we know how the little things can make all the difference.

AREAS OF FOCUS

We are committed to discovering and developing first-in-class or best-in-class oral small-molecule and injectable protein therapeutics to treat hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to identify the target protein in advance, and by determining the molecular structure of the protein, our scientists can design an optimal drug that uniquely fits a cell or binding site.

Our pipeline includes investigational therapies for HAE, a potentially life-threatening rare disease characterized by repeated painful and unpredictable swelling attacks, and other rare and serious diseases including Netherton syndrome and diabetic macular edema (DME). We are also developing therapies for the treatment of complement-mediated diseases, including oral inhibitors for all major pathways of the complement system.

We are a commercial-stage biotech company with US headquarters in Durham, North Carolina, and our Discovery Center of Excellence is rooted in Birmingham, Alabama, with many other regional offices around the world.

OUR NUMBERS*

FOUNDED
1986

450+
EMPLOYEES
WORLDWIDE

IPO
1994

49
COUNTRIES
WHERE OUR
MEDICINES
HELP
PATIENTS

NASDAQ
BCRX

1 IN 10,000-
1 IN 50,000
HAE PATIENTS
WORLDWIDE¹

We pursue challenging diseases and design molecules with expert chemistry knowledge and multidisciplinary collaboration to help change how rare diseases progress - and how a patient feels.

7,000+
rare diseases known

>90%
do not have
an approved treatment^{2,3}

2
COMMERCIAL
PRODUCTS

orladeyo[®]
(berotralstat) capsules 150 mg
oral tablets 72-96-108-132 mg

Rapivab[®]
peramivir injection

orladeyo.com

rapivab.com

1. Bernstein JA. HAE update: epidemiology and burden of disease. Allergy Asthma Proc. 2013;34(1):3-6
2. National Center for Advancing Translational Sciences. <https://rarediseases.info.nih.gov/>
3. The Power of Being Counted | RARE-X. <https://rare-x.org/wp-content/uploads/2022/05/be-counted-052722-WEB.pdf> [Alexion co-authored this report].





A PASSION FOR

SUPPORTING

PATIENTS

It's why we do what we do: creating treatments that have the potential to not just move the needle—but move mountains—for people living with hereditary angioedema (HAE) and other rare diseases, restoring a sense of freedom for them and their loved ones.

The reason we're all here—from those of us on the front lines or behind the scenes in our own labs, to those in our home offices and around the world—united toward getting the right treatments into the hands of patients who need them most. It's the unwavering dedication to a greater goal that

encourages everyone here to have a stake, a say, in our success; to be truly invested in what we're trying to achieve together.

It's what transforms employees into owners, converts challenges into triumphs and empowers the extraordinary.

“ Our company is about our patients, and I think it's super important that we put ourselves in patients' shoes and can understand and empathize with what they've gone through so that we can do our jobs better. I think that level of awareness of what patients are living through is super critical so that the work we do is even more relevant to what their needs are.”

— JINKY ROSSELLI
Chief Data & Insights Officer

What we value

LAUGHTER
especially at ourselves

SELF-AWARENESS
we can always learn and get better

BOLDNESS
courage to speak our dream

OWNERSHIP
be an owner, not a renter

INTEGRITY
always do the right thing

RESILIENCY
never give up

CARING
for patients and for each other

EXPERIENCE
either we have it or we know how to find it